Product Description
Mechanisms of Action: Tubulin Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Breast Cancer|Colorectal Cancer|Mesothelioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-002083-98 | P2 |
Terminated |
Breast Cancer |
2008-12-15 |
|
| 3128K1-201 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2005-02-01 |
|
| 3128K1-200 | P2 |
Completed |
Colorectal Cancer |
2004-02-01 |
|
| CTR20202551 | N/A |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |